METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo aims to shrink tough head and neck cancers
Disease control OngoingThis study tests whether adding an immunotherapy drug (cemiplimab) to low-dose chemotherapy can shrink tumors in people with head and neck cancer that has returned or spread. About 46 adults who have not had prior treatment for advanced disease will receive the combination. The m…
Matched conditions: METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated May 17, 2026 02:15 UTC
-
New combo aims to boost immunotherapy for head and neck cancer
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard immunotherapy (pembrolizumab) helps people with head and neck cancer that has returned or spread. About 52 adults with incurable, measurable disease will receive either the combo or pembrolizumab alone. The goal is …
Matched conditions: METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
Radiation boost may improve immunotherapy for advanced head and neck cancer
Disease control OngoingThis study compares two treatments for head and neck cancer that has spread to other parts of the body. All participants receive the immunotherapy drug pembrolizumab plus chemotherapy. Half also get targeted radiation to their tumors. The goal is to see if adding radiation helps …
Matched conditions: METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:02 UTC